Andra AP fonden Sells 72,300 Shares of DexCom, Inc. $DXCM

Key Points

• Andra AP fonden cut its DexCom position by 62% in the second quarter, selling 72,300 shares and retaining 44,363 shares valued at approximately $2.99 million.
• Institutional investors own 97.75% of DexCom, while several major funds—including UBS Asset Management and Janus Henderson—expanded their holdings.
• DexCom reported quarterly earnings of $0.70 per share and revenue of $1.31 billion, exceeding analyst estimates; analysts maintain a “Moderate Buy” consensus with an average price target of $89.08.

Andra AP fonden reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 62.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,363 shares of the medical device company's stock after selling 72,300 shares during the period. Andra AP fonden's holdings in DexCom were worth $2,988,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in DexCom by 15.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company's stock worth $758,487,000 after purchasing an additional 1,515,702 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of DexCom by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company's stock valued at $727,842,000 after acquiring an additional 42,411 shares in the last quarter. Norges Bank acquired a new stake in shares of DexCom in the fourth quarter valued at about $483,356,000. Janus Henderson Group PLC increased its position in shares of DexCom by 32.3% in the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company's stock valued at $166,077,000 after acquiring an additional 645,534 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of DexCom in the second quarter valued at about $173,237,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Down 2.0%

Shares of DXCM stock opened at $87.73 on Thursday. The firm has a 50 day moving average price of $84.97 and a two-hundred day moving average price of $73.63. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $33.11 billion, a PE ratio of 34.68, a price-to-earnings-growth ratio of 1.50 and a beta of 1.42. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm's revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.48 earnings per share. As a group, analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current year.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 2,565 shares of the business's stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $88.37, for a total value of $226,669.05. Following the completion of the sale, the executive vice president owned 126,043 shares of the company's stock, valued at approximately $11,138,419.91. The trade was a 1.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $85.32, for a total transaction of $170,640.00. Following the completion of the sale, the director directly owned 48,852 shares of the company's stock, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 73,504 shares of company stock worth $5,651,332. 0.28% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on DXCM shares. Mizuho increased their price target on DexCom from $90.00 to $95.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. UBS Group set a $96.00 price target on DexCom and gave the stock a "buy" rating in a research report on Tuesday, July 28th. Stifel Nicolaus set a $95.00 price objective on DexCom and gave the stock a "buy" rating in a research note on Friday, July 31st. Benchmark increased their price objective on DexCom from $77.00 to $82.00 and gave the company a "buy" rating in a report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft started coverage on DexCom in a report on Tuesday, June 23rd. They issued a "buy" rating and a $86.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $89.08.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company's products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.